Genmab (Otc) ( (GMAB) ) has released its Q3 earnings. Here is a breakdown of the information Genmab (Otc) presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the development of antibody therapeutics for cancer treatment. The company operates in the global biotechnology sector and is known for its innovative DuoBody technology platform.
In its latest earnings report for the first nine months of 2025, Genmab announced a significant revenue increase of 21% compared to the same period in 2024, reaching $2,662 million. The company also highlighted its proposed acquisition of Merus N.V., a clinical-stage biotechnology company, and notable advancements in its late-stage product pipeline, including FDA designations and trial successes.
Key financial metrics revealed that Genmab’s revenue growth was primarily driven by increased royalties from DARZALEX and Kesimpta, as well as higher net product sales of EPKINLY. The company’s operating profit rose to $1,007 million, a substantial increase from $662 million in the previous year. Strategic developments included the FDA granting Breakthrough Therapy Designation to Rina-S in advanced endometrial cancer and priority review for epcoritamab in follicular lymphoma.
Looking ahead, Genmab maintains its financial guidance for 2025, projecting continued revenue growth driven by its robust product pipeline and strategic acquisitions. The company’s management remains focused on accelerating its late-stage pipeline and expanding its global market presence, aiming to sustain growth and solidify its position as a leader in the biotechnology industry.